National Cancer Institute’s Fermentation Development Program

  • J. D. Douros
Part of the Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer book series (RECENTCANCER, volume 63)

Summary

The present National Cancer Institute (NCI) fermentation antineoplastic development program is reviewed. The program regarding the isolation of microorganisms, their fermentation, screening productivity, antineoplastic structures of interest, and future plans follows.

NCI initiated its fermentation program in 1956 and, during the next four years, the primary organisms isolated and screened for their abilities to produce antineoplastic agents were fungi. Undoubtedly, the use of fungi was dictated by the early success of penicillin as an antimicrobial agent. [2] From 1960 to 1975, the isolation and fermentation of streptomycetes dominated the program. During this same period, Streptomyces were the most prolific organisms for the production of novel antimicrobial antibiotics, but this does not necessarily mean they would be the best producers of antineoplastic agents. During these years approximately 700 microbial metabolites, obtained by worldwide surveillance or by NCI sponsored research, were tested in various NCI in vivo screens (L1210, S180, Ca 755, Walker 256) While this research resulted in the discovery of several excellent antineoplastic antibiotics such as streptozotocin, mithramycin, adriamycin (Italian) and bleomycin (Japanese), it was decided that other unusual organisms might yield different, and possibly better, anticancer agents.

Streptomyces have been an excellent source of a number of antimicrobial antibiotics, however, under the test conditions previously used, these organisms have been a relatively poor source of antifungal or antiviral substances. [2] Results of the NCI program, during this period, indicated that the same agents were being rediscovered at a high rate. The program was redirected in late 1974. The emphasis was placed on obtaining a multitude of new organisms; to ferment them under unusual conditions, and to utilize more prescreens to obtain new types of structures. Hopefully, these efforts would increase the number of in vivo active beers and thus increase the total number of novel compounds isolated. Prescreens should conserve effort in that fewer fermentation broths would be subjected to in vivo testing. Prescreens may also identify new activities which might be caused by new chemical structures and simultaneously increase the efficiency of the in vivo tests. The following data summarizes the current NCI contract research program. However, since the materials isolated during 1975 and 1976 have not yet reached clinical trials, it is too early to obtain a good measure of success of the overall program. Preliminary data indicates success in obtaining novel antineoplastic agents active against animal tumors.

Keywords

Xylose Fructose Microbe Chitin Fusarium 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Betts, R. E., Walters, D. E., Rosazza, J. P.: Microbial transformations of antitumor compounds. I. Conversions of acronycine to 9-hydroxyacronycine by Cunninhamella echinulate. J. Med. Chem. 17,599–602(1974).PubMedCrossRefGoogle Scholar
  2. 2.
    Brian, P. W.: Antibiotics produced by fungi. Botanical Rev. 17, 357–430 (1951).CrossRefGoogle Scholar
  3. 3.
    Dagley, S., Evans, W. C., Ribbons, D. W.: New pathways in the oxidative metabolism of aromatic compounds by microorganisms. Nature 88, 560–566 (1960).CrossRefGoogle Scholar
  4. 4.
    Davis, J. B., Raymond, R. L.: Oxidation of alky substituted cyclic hydrocarbons by a Nocardia during growth of N-alkanes. Appl. Microbiol. 9, 383–388 (1966).Google Scholar
  5. 5.
    Douros, J. D., Jr.: Lower plants as a source of anticancer drugs. Cancer Treat. Rep. 60, 1069–1080 (1976).PubMedGoogle Scholar
  6. 6.
    Douros, J. D., Jr., Frankenfeld, J. W.: Oxidation of alkylbenzenes by a strain of Micrococcus cerificans growing on n-pariffins. Appl. Microbiol. 16, 320 (1968).PubMedGoogle Scholar
  7. 7.
    Douros, J. D., Jr., Frankenfeld, J. W.: Production of cinnamic acid from alkylbenzenes by soil microorganisms, effects of culture conditions on yield. Appl. Microbiol. 16, 532 (1968).PubMedGoogle Scholar
  8. 8.
    Douros, J. D., Jr., Frankenfeld, J. W.: Fermentation Process for Preparing Cinnamic Acid and 5-phenyl valeric acid. U.S. 3, 301,766.Google Scholar
  9. 9.
    Fidler, I. J., Budmen, M. B., Hanna, M. G., Jr.: Characterization of in vitro reactivity by BCG treated guinea pigs to syngeneic line-10 hepatocarcinoma. Cancer Immunology Immunotherapy 1, 179–186(1976).CrossRefGoogle Scholar
  10. 10.
    Gordon, M. H.: A simulation study of the preclinical development of anticancer drugs. Cancer Chemother. Rep. Part 3 5, 65–78 (1974).Google Scholar
  11. 11.
    Hanka, L. J.: Proceedings of the 5th International Congress of Chemotherapy, Sec. B9/2 351–357 (1967).Google Scholar
  12. 12.
    Hanna, M. G., Jr., Peters, L. C.: The efficacy of BCG induced tumor immunity in guinea pigs with regional and systemic malignancy. Cancer Immunology Immunotherapy 1, 171–177 (1976).CrossRefGoogle Scholar
  13. 13.
    Murphree, D. S., Cunningham, L. S., Hwang, K. M., Sartorelli, A. C.: Effects of adriamycin on surface properties of sarcoma 180 ascites Cells. Biochem. Pharmacol. 25,1227–1231 (1976).PubMedCrossRefGoogle Scholar
  14. 14.
    Raymond, R. L., Jamison V. W., Hudson, J. O.: Microbial Hydrocarbon Co-Oxidation. I. Appl. Microbiol. 15, 857–865 (1967).PubMedGoogle Scholar
  15. 14.
    Raymond, R. L., Jamison V. W., Hudson, J. O.: Measure plant lectin induced cell agglatination. Cancer Res. 34, 3396–3402 (1974).Google Scholar
  16. 15.
    Raymond, R. L., Jamison, V. W., Hudson, J. O.: Hydrocarbon co-oxidation in microbial systems. Lipids 6, 453–457 (1971).PubMedCrossRefGoogle Scholar
  17. 16.
    Sartorelli, A. C., Murphree, S. A., Hwang, K. M.: A quantitative spectrophotometric method to measure plant lectin induced cell agglutination. Cancer Res. 34, 3396–3402 (1974).PubMedGoogle Scholar
  18. 17.
    Sartorelli, A. C.: Preliminary Data Report to NCI (1976).Google Scholar
  19. 18.
    Sebek, O. K.: Microbial conversion of antibiotics. Lloydia 37, 115–133 (1974).PubMedGoogle Scholar
  20. 19.
    Smith, R. V., Rosazza, J. P.: Microbial models of mammalian metabolism. Aromatic hydroxylation. Arch. Biochem. Biophys. 161, 551–558 (1974).CrossRefGoogle Scholar
  21. 20.
    Smith, R. V., Rosazza, J. P.: Microbial systems for the study of drug biotransformations. Biotechnol. Bioeng. 17, 785–814 (1975).CrossRefGoogle Scholar
  22. 21.
    Society of American Bacteriologists: Manual of Microbiological Methods, New York: McGraw-Hill Book Co. 1957.Google Scholar
  23. 22.
    Umezawa, H.: Enzyme Inhibitors of Microbial Origin. Tokyo University: Tokyo Press 1972.Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1978

Authors and Affiliations

  • J. D. Douros

There are no affiliations available

Personalised recommendations